secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001193125-22-302915
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix reports positive Phase 1 data for BTK degrader NX-2127; 33% ORR in heavily pretreated CLL
--------------------------------------------------------------------------------

- ORR of 33% (95% CI 12-62%) in 23 CLL patients who failed median 5 prior therapies, 78% prior BTK+BCL2 inhibitors.
- 48% of CLL patients had BTK resistance mutations; NX-2127 showed activity regardless of mutational status.
- Median follow-up 5.6 months; 14 of 23 CLL patients remained on treatment as of Sept 21, 2022 data cut.
- BTK mutations resistant to covalent and non-covalent inhibitors remained susceptible to degradation by NX-2127.
- Safety profile consistent with prior Phase 1a results and BTK-targeted therapies in heavily pretreated patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000119312522302915/0001193125-22-302915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000119312522302915/d411325d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-302915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer